Role of endocrine therapy in the neoadjuvant surgical setting
- J. Michael Dixon MB ChB, MD, FRCS
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Most neoadjuvant (preoperative) therapy of breast cancer has involved the use of chemotherapy, but primary endocrine therapy has also been shown to be effective in postmenopausal women with estrogen receptor-positive tumors. Neoadjuvant therapy can reduce tumor volume, permitting surgery for otherwise inoperable tumors or allowing breast-conserving surgery rather than mastectomy for operable tumors. The preoperative treatment setting also allows for assessment and comparison of responses to different agents, which may then be used in the adjuvant therapy setting following surgery. Since tumor biopsies can be obtained before, during, and after preoperative therapy, the relationship between biomarkers and response or resistance to surgery can be investigated. In the Edinburgh Breast Unit, neoadjuvant endocrine therapy with aromatase inhibitors has been more successful than with tamoxifen. Recurrence rates following preoperative endocrine therapy and breast-conserving surgery have been acceptably low, provided that radiation therapy was also administered postoperatively. Both the probability of response to neoadjuvant letrozole or tamoxifen and the degree of tumor shrinkage increased as estrogen receptor expression increased, consistent with the results of other studies. Attempts to identify biomarkers of response to neoadjuvant endocrine therapy are under way, with early indications that reduced cell proliferation 14 days after initiation of treatment correlates with responses to tamoxifen.
- Bear HD. Indications for neoadjuvant chemotherapy for breast cancer.Semin Oncol 1998;25(suppl 3):3–12.
- Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol 1997;15:2483–93.
- Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 1998;16:2672–85.
- Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.Eur J Cancer 2002; 38:2214–21. CrossRef
- Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.Ann Oncol 1998; 9:1179–84. CrossRef
- Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only.Br J Surg 1991;78:213–7.
- Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer.Breast Cancer Res Treat 2001;66:191–9. CrossRef
- Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.Clin Cancer Res 2000;6:2229–35.
- Dixon JM, Anderson T, Miller WR. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer [abstract 1908].Proc Am Assoc Cancer Res 2001;20:40b.
- Dixon JM, Love CD, Renshaw L, et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.Endocr Relat Cancer 1999;6:227–30. CrossRef
- Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study.Ann Oncol 2001;12:1527–32. CrossRef
- Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.J Clin Oncol 2001; 19:3808–16.
- Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant letrozole: the Edinburgh experience [abstract 264].Breast Cancer Res Treat 2002;76(suppl 1):S75.
- Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast.Ann Surg 1995;222:612–8. CrossRef
- Moneer M, El-Didi M, Khaled H. Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy? A pathological assessment.Breast 1999;8:315–9. CrossRef
- Miller WR, Dixon JM. Endocrine and clinical endopoints of exemestane as neoadjuvant therapy.Cancer Control 2002;9(suppl):9–15.
- Role of endocrine therapy in the neoadjuvant surgical setting
Annals of Surgical Oncology
Volume 11, Issue 1 Supplement, pp 18S-23S
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Breast-conserving surgery
- Industry Sectors
- Author Affiliations
- 1. Academic Office, Edinburgh Breast Unit, Western General Hospital, EH4 2XU, Edinburgh, UK